Works matching AU Merchant, Mark


Results: 57
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20

    Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.

    Published in:
    PLoS ONE, 2017, v. 12, n. 10, p. 1, doi. 10.1371/journal.pone.0185862
    By:
    • Merchant, Mark;
    • Moffat, John;
    • Schaefer, Gabriele;
    • Chan, Jocelyn;
    • Wang, Xi;
    • Orr, Christine;
    • Cheng, Jason;
    • Hunsaker, Thomas;
    • Shao, Lily;
    • Wang, Stephanie J.;
    • Wagle, Marie-Claire;
    • Lin, Eva;
    • Haverty, Peter M.;
    • Shahidi-Latham, Sheerin;
    • Ngu, Hai;
    • Solon, Margaret;
    • Eastham-Anderson, Jeffrey;
    • Koeppen, Hartmut;
    • Huang, Shih-Min A.;
    • Schwarz, Jacob
    Publication type:
    Article
    21
    22
    23

    Immuno-PET of the Hepatocyte Growth Factor Receptor Met Using the 1-Armed Antibody Onartuzumab.

    Published in:
    Journal of Nuclear Medicine, 2012, v. 53, n. 10, p. 1592, doi. 10.2967/jnumed.111.102293
    By:
    • Jagoda, Elaine M.;
    • Lang, Lixin;
    • Bhadrasetty, Veerendra;
    • Histed, Stephanie;
    • Williams, Mark;
    • Kramer-Marek, Gabriela;
    • Mena, Esther;
    • Rosenblum, Lauren;
    • Marik, Jan;
    • Tinianow, Jeff N.;
    • Merchant, Mark;
    • Szajek, Lawrence;
    • Paik, Chang;
    • Cecchi, Fabiola;
    • Raffensperger, Kristen;
    • Jose-Dizon, Joe-Marie;
    • Bottaro, Donald P.;
    • Choyke, Peter
    Publication type:
    Article
    24
    25
    26

    Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer.

    Published in:
    Cancer (0008543X), 2024, v. 130, n. 11, p. 1940, doi. 10.1002/cncr.35222
    By:
    • Mutch, David;
    • Voulgari, Athina;
    • Chen, Xian;
    • Bradley, William H.;
    • Oaknin, Ana;
    • Perez Fidalgo, José Alejandro;
    • Montosa, Fernando Galvez;
    • Herraez, Antonio Casado;
    • Holloway, Robert W.;
    • Powell, Matthew A.;
    • Nowicka, Malgorzata;
    • Schaefer, Gabriele;
    • Merchant, Mark;
    • Yan, Yibing
    Publication type:
    Article
    27

    Loss of the Serine/Threonine Kinase Fused Results in Postnatal Growth Defects and Lethality Due to Progressive Hydrocephalus.

    Published in:
    Molecular & Cellular Biology, 2005, v. 25, n. 16, p. 35, doi. 10.1128/MCB.25.16.7054-7068.2005
    By:
    • Merchant, Mark;
    • Evangelista, Marie;
    • Shiuh-Ming Luoh;
    • Frantz, Gretchen D.;
    • Chalasani, Sreedevi;
    • Carano, Richard A. D.;
    • Van Hoy, Marjie;
    • Ramirez, Julio;
    • Ogasawara, Annie K.;
    • McFarland, Leanne M.;
    • Filvaroff, Ellen H.;
    • French, Dorothy M.;
    • De Sauvage, Frederic J.
    Publication type:
    Article
    28

    Suppressor of Fused Regulates Gli Activity through a Dual Binding Mechanism.

    Published in:
    Molecular & Cellular Biology, 2004, v. 24, n. 19, p. 8627, doi. 10.1128/MCB.24.19.8627-8641.2004
    By:
    • Merchant, Mark;
    • Vajdos, Felix F.;
    • Ultsch, Mark;
    • Maun, Henry R.;
    • Wendt, Ulrich;
    • Cannon, Jennifer;
    • Desmarais, William;
    • Lazarus, Robert A.;
    • De Vos, Abraham M.;
    • De Sauvage, Frederic J.
    Publication type:
    Article
    29
    30
    31

    A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.

    Published in:
    NPJ Precision Oncology, 2018, v. 2, n. 1, p. N.PAG, doi. 10.1038/s41698-018-0051-4
    By:
    • Wagle, Marie-Claire;
    • Kirouac, Daniel;
    • Klijn, Christiaan;
    • Liu, Bonnie;
    • Mahajan, Shilpi;
    • Junttila, Melissa;
    • Moffat, John;
    • Merchant, Mark;
    • Huw, Ling;
    • Wongchenko, Matthew;
    • Okrah, Kwame;
    • Srinivasan, Shrividhya;
    • Mounir, Zineb;
    • Sumiyoshi, Teiko;
    • Haverty, Peter M.;
    • Yauch, Robert L.;
    • Yan, Yibing;
    • Kabbarah, Omar;
    • Hampton, Garret;
    • Amler, Lukas
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39
    40

    Presence of chitinase enzymes in crocodilians.

    Published in:
    Acta Herpetologica, 2014, v. 9, n. 2, p. 139, doi. 10.13128/Acta_Herpetol-13237
    By:
    • SIROSKI, PABLO A.;
    • POLETTA, GISELA L.;
    • PARACHÚ MARCÓ, MARÍA V.;
    • ORTEGA, HUGO H.;
    • MERCHANT, MARK E.
    Publication type:
    Article
    41
    42
    43
    44
    45

    Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic--pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1 H-pyrazolo[3,4- b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor

    Published in:
    Xenobiotica, 2011, v. 41, n. 4, p. 327, doi. 10.3109/00498254.2010.542500
    By:
    • Liederer, Bianca M.;
    • Berezhkovskiy, Leonid M.;
    • Dean, Brian J.;
    • Dinkel, Vikki;
    • Peng, Jing;
    • Merchant, Mark;
    • Plise, Emile G.;
    • Wong, Harvey;
    • Liu, Xingrong
    Publication type:
    Article
    46
    47

    Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non-Small Cell Lung Cancer.

    Published in:
    Science Translational Medicine, 2013, v. 5, n. 171, p. 1, doi. 10.1126/scitranslmed.3004438
    By:
    • Hegde, Ganapati V.;
    • de la Cruz, Cecile C.;
    • Chiu, Cecilia;
    • Alag, Navneet;
    • Schaefer, Gabriele;
    • Crocker, Lisa;
    • Ross, Sarajane;
    • Goldenberg, David;
    • Merchant, Mark;
    • Tien, Janet;
    • Lily Shao;
    • Roth, Leslie;
    • Siao-Ping Tsai;
    • Stawicki, Scott;
    • Zhaoyu Jin;
    • Wyatt, Shelby K.;
    • Carano, Richard A. D.;
    • Yanyan Zheng;
    • Sweet-Cordero, E. Alejandro;
    • Yan Wu
    Publication type:
    Article
    48
    49

    Erratum: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.

    Published in:
    Nature, 2013, v. 502, n. 7470, p. 258, doi. 10.1038/nature12659
    By:
    • Hatzivassiliou, Georgia;
    • Haling, Jacob R.;
    • Chen, Huifen;
    • Song, Kyung;
    • Price, Steve;
    • Heald, Robert;
    • Hewitt, Joanne F. M.;
    • Zak, Mark;
    • Peck, Ariana;
    • Orr, Christine;
    • Merchant, Mark;
    • Hoeflich, Klaus P.;
    • Chan, Jocelyn;
    • Luoh, Shiuh-Ming;
    • Anderson, Daniel J.;
    • Ludlam, Mary J. C.;
    • Wiesmann, Christian;
    • Ultsch, Mark;
    • Friedman, Lori S.;
    • Malek, Shiva
    Publication type:
    Article
    50

    Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.

    Published in:
    Nature, 2013, v. 501, n. 7466, p. 232, doi. 10.1038/nature12441
    By:
    • Hatzivassiliou, Georgia;
    • Haling, Jacob R.;
    • Chen, Huifen;
    • Song, Kyung;
    • Price, Steve;
    • Heald, Robert;
    • Hewitt, Joanne F. M.;
    • Zak, Mark;
    • Peck, Ariana;
    • Orr, Christine;
    • Merchant, Mark;
    • Hoeflich, Klaus P.;
    • Chan, Jocelyn;
    • Luoh, Shiuh-Ming;
    • Anderson, Daniel J.;
    • Ludlam, Mary J. C.;
    • Wiesmann, Christian;
    • Ultsch, Mark;
    • Friedman, Lori S.;
    • Malek, Shiva
    Publication type:
    Article